BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22536061)

  • 1. Experiences and perspectives on the GIST patient journey.
    Macdonald N; Shapiro A; Bender C; Paolantonio M; Coombs J
    Patient Prefer Adherence; 2012; 6():253-62. PubMed ID: 22536061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: qualitative insights using a global ethnographic approach.
    Guilhot F; Coombs J; Szczudlo T; Zernovak O; Paolantonio M; Bender C; Macdonald NJ; Shapiro A
    Patient; 2013; 6(2):81-92. PubMed ID: 23529848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
    Patel S
    Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of liver metastases of gastrointestinal stromal tumors (GIST).
    Vassos N; Agaimy A; Hohenberger W; Croner RS
    Ann Hepatol; 2015; 14(4):531-9. PubMed ID: 26019040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors.
    Blay JY; Rutkowski P
    Cancer Treat Rev; 2014 Mar; 40(2):242-7. PubMed ID: 23931926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Keung EZ; Fairweather M; Raut CP
    Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
    Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
    [No Abstract]   [Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
    Barrios CH; Blackstein ME; Blay JY; Casali PG; Chacon M; Gu J; Kang YK; Nishida T; Purkayastha D; Woodman RC; Reichardt P
    Eur J Cancer; 2015 Nov; 51(16):2423-33. PubMed ID: 26248685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
    Demetri GD
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.
    Zalcberg JR; Desai J
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):43-52. PubMed ID: 22369443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Similarities and differences in diagnosis and treatment of gastrointestinal stromal tumors between China, Japan and Korea: from expert consensus to cooperation prospect].
    Cao H; Wang M
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):812-819. PubMed ID: 31550818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
    Demetri GD
    Semin Oncol; 2011 Apr; 38 Suppl 1():S10-9. PubMed ID: 21419931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 19. Radiotherapy in the treatment of gastrointestinal stromal tumor.
    Knowlton CA; Brady LW; Heintzelman RC
    Rare Tumors; 2011 Oct; 3(4):e35. PubMed ID: 22355490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor.
    Agulnik M; Giel JL
    Am J Clin Oncol; 2014 Aug; 37(4):417-22. PubMed ID: 22772433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.